. "3 Sterile Needle and Syringe Access and Outreach and Education." Preventing HIV Infection among Injecting Drug Users in High Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press, 2006.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vlahov D, Astemborski J, Solomon L, Nelson KE. 1994. Field effectiveness of needle disinfection among injecting drug users. Journal of Acquired Immune Deficiency Syndromes. 7(7):760–766.
Vlahov D, Junge B, Brookmeyer R, Cohn S, Riley E, Armenian H, Beilenson P. 1997. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. Journal of Acquired Immune Deficiency Syndromes and HumanRetrovirology. 16(5):400–406.
Watters JK, Estilo MJ, Clark GL, Lorvick J. 1994. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. Journal of the American Medical Association. 271(2): 115–120.
Weber DJ, Barbee SL, Sobsey MD, Rutala WA. 1999. The effect of blood on the antiviral activity of sodium hypochlorite, a phenolic, and a quaternary ammonium compound. Infection Control and Hospital Epidemiology. 20(12):821–827.
Wiebel WW, Jimenez A, Johnson W, Ouellet L, Jovanovic B, Lampinen T, Murray J, O’Brien MU. 1996. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: A four-year prospective study. Journal of Acquired Immune Deficiency Syndromesand Human Retrovirology. 12(3):282–289.
Wood E, Tyndall MW, Spittal PM, Li K, Hogg RS, Montaner JS, O’Shaughnessy MV, Schechter MT. 2002. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS. 16(6):941–943.
Wood E, Kerr T, Spittal PM, Small W, Tyndall MW, O’Shaughnessy MV, Schechter MT. 2003. An external evaluation of a peer-run “unsanctioned” syringe exchange program. Journal of Urban Health. 80(3):455–464.
Wood E, Kerr T, Lloyd-Smith E, Buchner C, Marsh D, Montaner J, Tyndall M. 2004a. Methodology for evaluating Insite: Canada’s first medically supervised safer injection facility for injection drug users. Harm Reduction Journal. 1:9.
Wood E, Kerr T, Small W, Li K, Marsh D, Montaner J, Tyndall M. 2004b. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. Canadian Medical Association Journal. 171(7):731–734.
Wood E, Tyndall M, Lai C, Montaner J, Kerr T. 2006a. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crimes. Substance AbuseTreatment, Prevention, and Policy. 1:13.
Wood E, Tyndall M, Zhang R, Stoltz J, Lai C, Montaner J, Kerr T. 2006b. Attendance at supervised injecting facilities and use of detoxification services. New England Journal ofMedicine. 354(23):2512–2514.